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Abstract 
Objective: To qualitatively develop and test a set of candidate items for a new RA stiffness 
patient-reported outcome measure (PROM) that capture the patient perspective. This is an 
essential first step in PROM development, prior to quantitative development, assessment and 
validation.  
Methods: Focus groups further examined the previously developed stiffness conceptual 
model and explored the patient perspective regarding stiffness assessment. Data were 
analysed using thematic analysis. An iterative process of item development was then 
performed by the expert study team of researchers, patients and clinicians, based on the two 
qualitative datasets and informed by measurement theory and guidelines. Finally, these 
candidate items were tested using formal cognitive interview methodology and subsequently 
refined.  
Results: Sixteen RA patients from the UK participated in focus groups. Data confirmed the 
conceptual model of the RA patient experience of stiffness and provided insight into stiffness 
assessment including suggestions regarding patient-relevant stiffness assessment categories 
such as impact, location, and timing. These data informed the development of 77 candidate 
stiffness PROM items, including multiple formats for some. Eleven RA patients participated in 
cognitive interviews. Minor changes were made to items to enhance understanding and 32 
items were removed, resulting in 45 candidate PROM items. 
Conclusion: Rigorous qualitative methodology and considerable patient involvement has 
underpinned items for a new RA stiffness PROM with strong content validity. Crucially, patient 
involvement broadened assessment beyond ‘early morning stiffness duration,’ which may 
address existing PROM limitations. Items are now suitable for quantitative item reduction, 
structural development of the final PROM, and validation.  
 
Key words: Rheumatoid arthritis, stiffness, morning stiffness, early morning stiffness, patient-
reported outcome measure  
Funding: University of the West of England  
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Introduction 
RA is a chronic, systemic, inflammatory condition causing synovitis and resulting in pain, 
swelling and stiffness [1]. Early clinical observations recognised morning stiffness (MS) or 
early morning stiffness (EMS) as a common feature of RA [2] and as such its subjective 
assessment was included in original classification [3] and remission [4] criteria, and composite 
assessments of disease activity (for example, [5]). However, EMS/MS was omitted from 
remission and classification criteria updates, the DAS, and the RA core set because of poor 
measurement properties of available patient-reported outcome measures (PROMs) [6-10]. 
Therefore, there is currently no obligation to assess stiffness in routine clinical care or clinical 
trials.  
Despite this, stiffness remains frequently queried in research and clinical contexts and is a 
relevant symptom to RA patients. In research, MS is regularly employed as a study inclusion 
criterion and as an outcome measure [11]. Specifically, MS is one of the few PROs (alongside 
pain, function and patient global assessment (PtG)) reported in ≥25% of research studies [12]. 
It has also been employed as the primary outcome measure in current research into timed-
release glucocorticoid treatments [13], results from which will inform patient treatment in 
clinical practice. Clinically, stiffness is commonly observed in an RA population with a recent 
prevalence estimate of between 70-75% regardless of treatment status [14]. Clinicians report 
awareness [15] and regular assessment of MS [16], and use it as an important variable in 
decision-making for changing patients’ medication [17]. Presence of MS has also been found 
to be a determinant of earlier initiation of DMARDs in an RA population [18]. Importantly, 
patients report that stiffness has a significant impact on their life [15], specifically work life [19]. 
Yet despite the relevance and common use of stiffness, until recently it has rarely been the 
focus of research. However, recent qualitative work furthered understanding of the patient 
experience of this symptom and developed a conceptual model capturing patients’ 
experiences of RA stiffness [20]. This was reinforced by work performed in a US patient 
sample [21].  
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In work into remission and flare, stiffness assessment has been identified as an area requiring 
investigation [22, 23]. This is particularly relevant to determining remission in a clinical context 
as it has been suggested that MS is likely to affect patients being unable to meet the stringent 
ACR/EULAR Boolean remission criteria [24]. Yet both a systematic literature review of 
stiffness PROMs in the assessment of low disease activity or remission [25] and an update of 
that review across all disease activity states [26] concluded that there was insufficient 
evidence supporting current stiffness PROMs, no indication of which stiffness PROM to use, 
and that no current PROMs had been developed with patient involvement. This is a 
fundamental concern as PROM development guidelines state that the purpose of PROMs are 
to capture what is relevant to the population of interest [27]. The importance of appropriate 
content validity in the development of PROMs has also been reinforced by the 
recommendation to include qualitative underpinning and involve the relevant population in 
PROM development [28, 29]. A lack of content validity in current stiffness PROMs was 
indicated in recent qualitative work where patients described stiffness as more than just 
severity and duration and not exclusively experienced in the morning [20, 21]. This contrasts 
with the most commonly used PROM assessments, which capture only morning stiffness 
severity or duration [25]. Given the apparent inconsistency between current stiffness 
assessment and the patient experience of this symptom, the aim of this study was to: 1) clarify 
and/or expand the proposed stiffness conceptual model and obtain patient views on 
assessment; 2) develop and then 3) qualitatively test a set of candidate items for a new RA 
stiffness PROM that captures the patient perspective and demonstrates appropriate content 
validity resulting from development in accordance with best practice guidelines [27-29]. 
 
Patients and Methods 
Study methods involved patient focus groups, item development and patient cognitive 
interviews. Ethics approval was granted by the Leeds East Research Ethics Committee 
(13YH0050). 
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Focus groups 
Patients with clinician-diagnosed RA [3, 8], aged ≥18 years, with the ability to speak English 
unaided were recruited from a rheumatology outpatient department in a UK hospital. Patients 
were invited to participate by a researcher (SH) or research nurse. Purposeful sampling was 
employed, and a sampling frame ensured patients with a range of age, sex and disease 
duration were recruited. Sample size was determined based on current recommendations 
[30]. Prior to each focus group, patients gave written informed consent and completed a brief 
questionnaire containing demographic and clinical information (Health Assessment 
Questionnaire (HAQ) [31]; PtG [32]).  
A focus group topic guide was developed: Part A asked about participants experience of 
stiffness to confirm or elaborate on the stiffness conceptual model developed in previous 
qualitative work [20]; Part B asked participants’ about their views regarding how stiffness 
should be assessed. An iterative process which allowed ideas and concepts identified in early 
data collection to be explored in subsequent data collection was employed [33]. Focus groups 
were moderated by two researchers (SH, ED) and audio-recorded, transcribed verbatim and 
managed using Nvivo 10 [34], Microsoft Office Word and Excel 2013. Deductive analysis is 
driven by theoretical influences such as existing theory, previous research, or coding frames 
[35]. The coding frame identified in previous stiffness qualitative work [20] (Part A), and a 
framework developed based on questionnaire design literature [36] including the broad 
categories of: stem questions and anchors, response options, timeframe, layout and format 
(Part B) were applied to these data.  
 
Item (question) development 
Item development was then performed, involving an iterative process of discussion with the 
expert study team and subsequent item refinement. Items were developed based on the 
combined qualitative data from this focus group study and from previous qualitative work [20]. 
The process was informed by PROM development guidelines [27-29]. It was also influenced 
by consideration of measurement theory including the need for measurement tools to 
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demonstrate appropriate measurement properties [37], and consideration of the 2014 
OMERACT Filter which evaluates outcome measures against the concepts of truth (is the 
measure unbiased?), discrimination (is the measure sensitive and reliable?) and feasibility (is 
the measure understandable and time efficient for ease of use in clinical and research 
environments?) [38].  
 
Cognitive interviews 
All candidate items were then reviewed by each patient during cognitive interviews. Cognitive 
interviewing is a formal research methodology capturing the cognitive process of item 
response enabling identification of difficulties with questions or response option interpretation 
[39]. A separate sample of patients were recruited using the same criteria and methods as 
described above. Cognitive interviews were performed by one researcher (SH). Patients were 
asked to complete the candidate items as they would any questionnaire but to explain what 
they were thinking as they read the question and judged their answers. Data were audio-
recorded, transcribed verbatim and managed using Nvivo 10 [34] Microsoft Office Word and 
Excel 2013. Data were analysed deductively based on the four headings of the four-stage 
cognitive model: ‘Understanding’ (did the patient understand the question?), ‘Retrieval’ (was 
the patient able to retrieve from memory the information required?), ‘Judgement’ (was the 
patient able to make a judgement?) and ‘Response’ (was the patient able to select an 
appropriate response?) [39]. The candidate items were then refined based on the cognitive 
interview data and discussion with the expert study team to develop the final list of candidate 
items for the new RA stiffness PROM.  
 
Results 
Overall, 27 RA patients with a range of demographics participated (Table 1). 
 
Focus groups 
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16 RA patients (11 female (68.8%), median age 64.5 years (interquartile range (IQR) 57-72 
years, median disease duration 6.5 years (IQR 3.5-13 years) participated across three focus 
groups (Table 1), each lasting approximately 120 minutes.  
Focus group data supported our previous qualitative work [20] in a new sample of patients 
using a different method of data collection. Each previously identified theme within the 
conceptual model of the RA patient experience of stiffness (Part of having RA; Linked to 
behaviour and environment; Local and widespread; Highly variable; Impacts on daily life; 
Requires self-management) [20] was supported by the focus group data, enhancing the 
robustness of the model (Table 2). Patients are identified by study number, gender, and study 
identifier, for example: Study 2, Male, study identifier 10 [2-M-10]. 
Investigation into the patient perspective of stiffness assessment provided insight into stem 
question categories and their relevance to patients, and patient preferences regarding 
response options, timeframe, and format. Participants raised stem question categories 
including impact, location, timing, and stiffness after immobility (Table 3). Other considerations 
for measurement that patients raised included the relationship between stiffness and 
symptoms such as pain and inflammation: “[…] stiffness, yes or no, with pain, yes or no, with 
swelling, yes or no” [2-M-10], and the individual nature of stiffness: “It’s how you feel, not the 
average or somebody else” [2-M-05]. Patients provided clarification that ‘stiffness’ was a 
patient relevant word: “Well, stiffness would be used, wouldn’t it?” […] Everybody says it, don’t 
they?” [2-M-10] “Yes” [multiple responders].  
Importantly, patients reported that they found the concept of stiffness duration difficult to 
answer, feeling it was hard to remember or quantify: “[…] when you come to the doctors and 
they say how long does it last, well, it’s about that long but it’s a guess really” [2-F-09] “Yes 
and you suddenly realise you haven’t got it then” [2-F-08] [agreement]. Patients stated that 
they were unsure what the start or endpoints for the clinician’s questions on duration were: 
“[…] we’re not working in the same way that the doctors are working, you know. In our minds 
we’re not sort of sitting there timing it” [2-F-16] [agreement and laughter] “Oh I am thoroughly 
unstiffened, no […] that’s not the real world” [2-F-16]. Additionally, duration questions were 
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not felt to capture the whole experience of stiffness because they focused on morning 
stiffness: “[…] if they’re [clinician] just looking at morning stiffness, then that doesn’t capture 
the general on-going seizing up through the day stiffness, sometimes it does but quite often, 
well it doesn’t at all and morning stiffness for me is mostly where my RA is in a flare or it’s not 
well managed […] at the moment it’s sort of fairly okay-ly managed so I’m not getting a lot of 
morning stiffness, but I do seize up through the day” [2-F-16]. Patients reflected that it was the 
clinician’s insistence on asking about morning stiffness that led to it being discussed, but 
limiting it to mornings was not particularly relevant to them: “I think, now we’re talking about it, 
we only talk about the morning because that’s what you ask us” [2-F-01] [laughter] “That’s 
right, that’s right” [2-M-05] “But it is, it’s after anytime” [2-F-01] “Any time of day really” [2-F-
04].  
Patients also discussed their preferences regarding relevant response options and layout 
focusing on the importance of simplicity and brevity: “Yes, less options” [2-M-06] “Yes, less 
options” [2-M-10] “More straightforward questions, less options” [2-M-06]. 
 
Item development 
These focus group data on stiffness experience and assessment were combined with data 
from the previous qualitative work underpinning the conceptual model of the patient 
experience of stiffness [20] and were mapped on to each other to form the basis for item 
development. From this, stem questions, response options, timeframe, and layout and format 
were designed in an iterative process involving the expert study team of researchers, patients, 
and clinicians. This process was informed by measurement theory [37, 38], PROM 
development guidelines [27-29], and consideration of the purpose of the PROM. Iterations of 
item development were captured in tracking tables [27] to enable checking and moving 
backward and forward through these data.  
Specifically in relation to the development of item response options, measurement theory 
literature suggested that four or five response options are preferable given that they place less 
burden on responders yet are still precise [40], while a number of rheumatology PROMs with 
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which RA patients may be familiar (e.g. HAQ [31] and Bristol Rheumatoid Arthritis Fatigue 
Multidimensional Questionnaire (BRAF) [41]) use four response options. This was consistent 
with the focus group preference for few and simple response options; thus both the literature 
and research informed the development of item response options. Additionally, 24 items were 
presented in several formats (visual analogue and numerical rating scales (VAS/NRS) and 
Likert scales), in an attempt to discern the preferred format.     
Overall, a bank of 77 candidate items were designed. These included the 24 items presented 
in multiple formats and six current stiffness PROM items (Table 4) identified in the literature 
review [25, 26]. Items were formatted into a paper questionnaire for further qualitative testing 
using cognitive interviews. To reduce participant burden, only one version of items presented 
in multiple formats were included in the questionnaire but all versions were discussed with all 
participants. 
 
Cognitive interviews 
11 RA patients (7 female (63.6%), median age 61 years (IQR 56-77 years, median disease 
duration 5 years (IQR 2-20 years, Table 1) participated in cognitive debriefing of all candidate 
items, each lasting approximately 60 minutes.  
Items were generally well understood. No difficulties were identified under the heading of 
‘Retrieval’. Minor difficulties were identified with retained items under the headings of 
‘Understanding’ (n=34), ‘Judgement’ (n=13), and ‘Response’ (n=18). These required changes, 
which although only minor, significantly improved the clarity and understanding of items. An 
example of a change made under the heading of ‘Understanding’ was in the item ‘Has stiffness 
made it difficult to do fine movements? For example, do up buttons on a shirt or cardigan?’ 
The seasonal nature of the item was highlighted: "Well, it’s this time of year, you don’t do up 
buttons, do you? [3-M-03]”. This item was therefore edited to be more broadly relevant, based 
on an example suggested in the previous qualitative work: ‘Has RA stiffness made it difficult 
to do fine movements (for example, write with a pen)?’ An example under the heading of 
‘Judgement’ included the observation that items requiring factual information were difficult to 
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make a judgement on. For example with the item ‘How much has joint damage contributed to 
your experience of stiffness?’ (intended to differentiate between inflammatory and mechanical 
stiffness), one patient stated: "That one is a bit hard to know because unless you have an x-
ray or something you don’t really know" [3-F-09]. These items were either edited or removed. 
Under the heading of ‘Response’, it appeared that some layouts led participants to select 
answers they did not intend: “Oh, did you say that one [answer] was ‘very much so’?” [SH] […] 
“Oh yes, got it in the wrong one, haven’t I?” [3-F-06]. As a result, the layout was changed, 
substituting a grid for boxes to ensure that the appropriate response option could be marked. 
Also in relation to ‘Response’, items using different response option formats (VAS/NRS/Likert 
scale) were discussed. Although patients described advantages and limitations with all 
formats, NRS were described as easy and clear: “I think if you grade it up to 10 it is probably 
easier in people’s minds […]” [3-F-09], and therefore were retained. 
 
Overall, minor changes were made to items for consistency and to improve clarity and 
understanding. Thirty-six of the 77 items were removed either because they had alternative 
formats to the retained NRS format, or because they contained information already captured 
in other items; four items were added based on patient suggestions. These included items to 
capture stiffness location, stiffness perceived as being different to usual and two items 
capturing stiffness perceived to be a result of joint damage. The current stiffness PROM item 
capturing MS on a VAS was also replaced by another current stiffness PROM item from the 
literature capturing stiffness rather than MS (Table 4). A final bank of 45 candidate items 
(Table 5), including six current stiffness PROM items from the literature (Table 4), were defined 
as suitable to take forward into further testing for quantitative item reduction, structural 
development of the final PROM and validation.  
 
Discussion 
This body of work demonstrates that collaboration with patients to better characterise and 
assess the patient experience of stiffness, results in a candidate list of items that assess 
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stiffness in an understandable and patient relevant way. Previous qualitative work in the UK 
[20] and US [21] demonstrated considerable similarities and improved understanding of the 
patient experience of stiffness in patients with RA. The conceptual model of RA stiffness [20] 
which emerged from that work was further explored here as part of the focus group 
discussions, where the model was confirmed in a new population of RA patients using a 
different qualitative method, enhancing the rigor of the model [42]. This is key as it supports 
universality of the conceptual model themes with both local and international work. 
Importantly, these qualitative studies demonstrated that RA patient descriptions and 
assessment of stiffness are much broader than, and in some cases inconsistent with, those 
captured in existing stiffness PROMs. While this had been suggested in previous qualitative 
work [20, 21], the results presented here enabled confirmation and further elaboration of these 
suggestions in an approach that focused on the development of appropriate stiffness 
assessment. For example, while current stiffness PROMs capture morning stiffness duration 
or severity [25], RA patients describe stiffness as not exclusive to the morning [20, 21] and in 
the current study expressed difficulties with responding to items that focus solely on this 
timeframe. Furthermore, the apparent multidimensional nature of stiffness identified in the 
conceptual model particularly the impact that stiffness has on patients’ lives [20] was here 
identified as a relevant stem question category (Table 3), and challenges the narrow focus of 
current PROM items focusing on severity and duration alone.  
The relevance of the concept of impact in patients with chronic conditions is not unique to the 
symptom of stiffness. The impact triad is a concept developed by patients and researchers, 
who propose that the severity of an outcome, its importance to patients, and their ability to 
self-manage it, all combine to form impact, and that these should all be captured in patient-
reported outcome assessment [43]. Impact is also a key component of other recently 
developed and well validated rheumatology outcome measures including the Psoriatic Arthritis 
Impact of Disease (PsAID) [44].  
The biomedical interpretation of stiffness relates the symptom to the circadian rhythms of pro-
inflammatory cytokines such as IL-6 which increase in the early morning [45]. However, patient 
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descriptions of stiffness not being exclusively experienced in the morning period challenge 
this biomedical interpretation in relation to patient-reported assessment of stiffness. This 
finding is supported by work with patients with PMR who similarly reported that stiffness is not 
purely experienced in the morning [46] and a recent Delphi study in the development of a core 
domain set for PMR where patients expressed a preference for ‘stiffness’ rather than ‘morning 
stiffness’ [47]. Work in PMR has also questioned the adequacy of duration as part of stiffness 
assessment [46]. This was consistent with the patient dislike of duration expressed in this 
study, and is concerning when considering that stiffness duration items are most frequently 
implemented in the assessment of stiffness in research trials [12].  
It is important to reiterate here that the purpose of a PROM is to capture the patient experience 
[27]. No current stiffness PROM appears to have been developed with such substantial 
involvement from the target population [26]. This demonstrates the added value of the new 
PROM items compared to those currently available. Poor content validity of current stiffness 
items may explain the inadequate psychometric performance of these items reported in the 
literature [6-10]. It also may explain the challenges reported with current items including that 
patients find completing duration items difficult, are often forced to report a cut-off time [48], 
and that patients have sometimes reported that they have no stiffness in a leader question 
asking about stiffness duration, only to later quantify the severity of that non-existent stiffness 
in a follow-up question [49]. This further supports the need for the involvement of the relevant 
population in the development of PROMs to enhance content validity and ensure that the 
patient experience is captured in outcome assessment.  
These results also relate to work within the OMERACT group. This article has addressed some 
of the key areas discussed at the breakout group within the OMERACT 2014 RA Flare Group 
Workshop [50] including the dislike of stiffness duration as a measure and the importance of 
the impact of stiffness from the patient perspective. It also drives forward the importance of 
further research on the topic of stiffness as highlighted on the research agenda of the report 
from the inaugural stiffness special interest group at OMERACT 2016 [26]. 
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This study provides evidence for the importance of performing cognitive interviews during 
PROM development, as suggested in guidelines [27-29]. Whilst the cognitive interviews only 
identified minor difficulties with items, the changes subsequently made to items were crucial 
to enhance acceptability to the intended population. If these difficulties had not been identified 
then subsequent inaccurate data collection may have resulted at later stages.  
These studies only recruited English-speaking patients from one UK based rheumatology 
outpatient department, which may affect generalisability. However, conceptual similarities 
within qualitative work in a heterogeneous US population have been reported [21], suggesting 
that these findings may be relevant in such populations. A further limitation relates to cognitive 
interviewing which is performed in a controlled research environment that may differ from use 
in an applied research or clinical setting. However, it is suggested that cognitive interviewing 
will identify the most significant problems with items [39], thus ensuring that items are 
appropriate for use in applied settings. Item development was based on data generated in 
qualitative studies with small samples. However, qualitative studies were rigorously performed 
in an iterative process with clinical, patient and research experts and data saturation [30] was 
achieved in all studies. Furthermore, the qualitative nature of the item development is a key 
strength of this work, consistent with recommended PROM development methodology [27-29] 
and recommendations from EULAR and OMERACT. 
The final 45 candidate items have face and content validity. They are now suitable for 
quantitative research to establish the smallest yet most internally consistent group of items to 
form a new RA stiffness PROM. This can then be subject to psychometric property evaluation, 
including construct and criterion validity, reliability, sensitivity to change, floor and ceiling 
effects [37]. After administration of the items to a wider patient sample (e.g. socio-
demographic, disease activity), classical and modern psychometric approaches can then be 
applied to determine the dimensionality of the construct, identify item redundancies and define 
a final, optimal set of items that best measures patient-reported stiffness. This work recognises 
stiffness as a relevant and recordable patient symptom and is a significant step towards a 
standardised assessment tool with appropriate measurement properties. 
Development and cognitive testing of candidate items for a new RA stiffness PROM 
14 
 
Key messages  
 RA patients describe and assess stiffness using wider concepts than captured in 
current stiffness PROMs  
 The RA patient experience of stiffness informed the development of items for a new 
PROM 
 This is a key step towards standardised stiffness assessment and recognition of a 
relevant patient symptom 
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Tables and Figures 
Table 1: Participant clinical and demographic data 
 FG 1 FG 2 FG 3 CI Total  
No. of participants  5 5 6 11 27 
Age       
Mean (SD) 66 (13.6) 68.4 (7.6) 58.8 (9.4) 65.5 (10.4) 64.6 (11.1) 
Median (IQR) 67 (53.5-75) 72 (59.5-75.5) 59.5 (51.3-66.8) 61 (56-77) 64 (56-73) 
Sex      
Female 4 3 4 7 18 
Male 1 2 2 4 9 
Disease duration       
Mean (SD) 5.8 (5.4) 11.2 (7.4) 13.8 (13.7) 9.5 (8.6) 10.1 (9.9) 
Median (IQR) 4 (1.5-11) 10 (5.5-17.5) 6 (3.5-29.8) 5 (2-20) 6 (3-16) 
HAQ*      
Mean (SD) 1.125 (0.7) 1.65 (0.5) 1.6 (0.8) 1.1 (0.6) 1.3 (0.7) 
Median (IQR) 1.375 (0.4-1.8) 1.75 (1.25-2) 1.875 (0.8-2.3) 1.2 (0.5-1.5) 1.5 (0.7-1.9) 
PtG      
Mean (SD) 4.12 (3.4) 4.7 (1.9) 3.8 (1.5) 5.0 (2.0) 4.5 (2.3) 
Median (IQR) 4.7 (0.3-7.7) 5.0 (2.6-6.7) 4.3 (2.2-5.2) 5.8 (3.3-6.8) 5.0 (2.4-6.1) 
FG=Focus group; CI=Cognitive interview; HAQ=Health Assessment Questionnaire (0-3, 3=most disabled); PtG=Patient Global Assessment (0-10, 0=very 
well, 10=very badly); *=data from two patients missing 
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Table 2: Patient quotes to support the stiffness conceptual model  
Original 
conceptual 
model  
Example quote supporting original model 
Part of having RA “I’ve always thought it [stiffness] was part of what we’ve got, actually.” 
[2-M-06]  [Agreement] 
 
Linked to 
behaviour and 
environment 
 
“It’s either keeping the same position for too long, like sitting on an 
aeroplane, for example. Or it’s when I’ve exercised too much” [2-F-01] 
“Yeah, yeah” [2-M-05] 
 
Local and 
widespread 
 
“My hips were stiff, my knees were stiff, everything was really hurting 
and that was within four hours” [2-F-14] 
 
Highly variable “[…] some days you’re going to be more stiff than others” [2-F-09] 
 
Impacts on daily 
life 
“Sometimes stiffness is prevention of doing things, like I used to enjoy 
sewing and threading a needle.  I can’t do that any longer, and that’s 
the stiffness, it’s not the pain.  There’s no pain in threading a needle, 
but I just can’t do it because my fingers […] parts of me just don’t work 
in the way that they should do […]” [2-F-08] 
 
Requires self-
management 
“[…] sometimes if the stiffness is bad you have to move your joints 
before you can actually get out of bed.” [2-F-16] “That’s right.” [2-M-11] 
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Table 3: Patient quotes to support stem question categories  
Stem question 
categories 
Example quote supporting stem question categories 
Stem question: 
Impact 
“I know it’s straight forward questions but it’s serious questions for 
people that can’t do it […] Comb your hair, brush your teeth, general 
daily, you think of what you do every day when you get up” [2-M-10] 
 
Stem question: 
Location  
“You know the picture they have of a person […] with the massive 
hands […] I always go to my consultant, that’s how it feels [laughs] […] 
it would be quite nice if you know, you could say, these bits are stiff” [2-
F-03] 
 
Stem question: 
Timing 
“[…] is there any aspect that particularly springs out when you think 
about assessing stiffness?” [SH] “When is it worse throughout the day? 
And is it on waking, is it mid-morning, is it lunchtime, is it afternoon, is 
it when you feel you’re tired? […] I think it’s important that you know 
which parts of the day that individuals have the worst problems? [2-F-
08] 
 
Stem question: 
Stiffness after 
immobility 
“So it’s not only during the night or first thing in the morning, it’s also” 
[2-F-02] [agreement] “It could be anytime” [2-F-04] “Yes, you’re right. 
Sitting here, for example” [2-M-05] [laughter] “Exactly!! After a period of 
immobility, whether it’s asleep or you’re awake” [2-F-01] “That’s a good 
word, I like that […] Immobility. If you’ve been immobile for, I don’t 
know, an hour. Whatever. Certainly longer. Then, how are your joints 
then? Nobody has asked that” [2-M-05]  
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Table 4: Current stiffness PROM items from literature 
Item concept Item 
MS severity How would you describe the overall level of morning stiffness you have 
had from the time you wake up? 
11-point NRS (0=No stiffness, 10=Very severe stiffness) 
 
MS severity How would you describe the overall level of morning stiffness you have 
had from the time you wake up? 
100mm VAS (0=No stiffness, 10=Extreme stiffness) 
 
MS severity How would you describe the overall level of morning stiffness you have 
had from the time you wake up? 
5-option Likert scale (No stiffness, Mild stiffness, Moderate stiffness, 
Severe stiffness, Very severe stiffness) 
 
MS duration Were your joints stiff when you woke up today? (Yes/No) If yes, how 
long did this extra stiffness last? 
6-option Likert scale (Less than 30 minutes, 30 minutes to an hour, 1-
2 hours, 2-4 hours, More than 4 hours but less than all day, All day) 
 
MS duration How long does your morning stiffness last from waking until maximum 
improvement occurs?  
3-option Likert scale (Up to 1 hour, 1-3 hours, More than 3 hours) 
 
MS duration How long does your morning stiffness last from waking until maximum 
improvement occurs? 
Minutes/Hours 
 
Severity*  Please circle the number that best describes the severity of your RA 
stiffness over a usual week when you are not in a flare? 
11-point NRS (0=No stiffness, 10=Extreme stiffness) 
MS=Morning stiffness; NRS=Numerical rating scale; VAS=Visual analogue scale; *=replaced MS 
severity item on VAS following cognitive interviews; Item sources provided in [25, 26] 
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Table 5: Final bank of 45 candidate items for new RA stiffness PROM 
Item 
no. 
Item wording Item response options 
1 Do you have any joints that are permanently stuck? Yes/No 
2 Over the past 7 days when have you experienced RA 
stiffness?  
Tick all that apply (In the night, In the 
morning, In the afternoon, In the evening, 
None of these) 
3 Have you experienced RA stiffness in your joints over 
the past 7 days? 
4-option Likert scale (No, not in any of my 
joints, Yes, in a few of my joints, Yes in 
many of my joints, Yes, in all of my joints)  
4 Over the past 7 days have you experienced RA 
stiffness all over? 
Yes/No 
5 Over the past 7 days has your RA stiffness been 
different to usual for you? 
 
5-option Likert scale (It has been much 
better than usual, It has been better than 
usual, It has been the same as usual, It has 
been worse than usual, It has been much 
worse than usual) 
6 Over the past 7 days has your RA stiffness been as 
variable (coming and going) as usual for you? 
 
5-option Likert scale (It has been much 
less variable than usual, It has been less 
variable than usual, It has been the same 
as usual, It has been more variable than 
usual, It has been much more variable than 
usual) 
7 Over the past 7 days have you experienced RA 
stiffness after a period of immobility (for example, 
after sitting for a while)? 
4-option Likert scale (No, not at all, Yes, a 
little, Yes, quite a lot, Yes, very much) 
8 Have you experienced RA stiffness in your body 
(outside of your joints) over the past 7 days? 
 
4-option Likert scale (No, not in any part of 
my body, Yes, in a few parts of my body, 
Yes, in many parts of my body, Yes, all 
over my body) 
9 Has RA stiffness affected your sleep? 4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
10 Has RA stiffness made it difficult to dress or undress 
yourself? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
11 Has RA stiffness made it difficult to wash yourself (for 
example, have a shower)? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
12 Has RA stiffness made it difficult to carry out your 
responsibilities or commitments? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
13 Has RA stiffness made it difficult to do your daily 
tasks or activities? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
14 Has RA stiffness made it difficult to chew? 4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
15 Has RA stiffness made it difficult to do hobbies or 
activities you enjoy? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
16 Has RA stiffness made it difficult to get out of bed? 4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
17 Has RA stiffness made it difficult to get up after sitting 
for a while? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
18 Have your daily tasks and activities required more 
effort because of RA stiffness? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
19 Has RA stiffness made you slower (for example, 
unable to do things quickly)? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
20 Has RA stiffness made it difficult to do fine 
movements (for example, write with a pen)? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
21 Has RA stiffness made it difficult to grip or hold 
things? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
22 Has RA stiffness made it difficult to open and close 
your fist? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
23 Has RA stiffness reduced your strength to do tasks? 4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
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Item 
no. 
Item wording Item response options 
24 Has your movement been restricted because of RA 
stiffness? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
25 Has RA stiffness made it difficult to balance without 
physically supporting yourself? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
26 Have you had to concentrate to move your body 
because of RA stiffness? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
27 Have you felt frustrated because of RA stiffness? 4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
28 Have you felt worried or concerned because of RA 
stiffness? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
29 Have you felt self-conscious because of RA 
stiffness? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
30 Has it taken you longer to do your daily tasks or 
activities because of RA stiffness? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
31 Have you had to change your plans or behaviour 
because of RA stiffness? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
32 Have you had to work around your RA stiffness (or 
do things in a different way)? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
33 Have you needed help (from others or gadgets) 
because of RA stiffness? 
4-option Likert scale (Not at all, A little, 
Quite a lot, Very much) 
34 Please circle the number that best describes the 
impact that RA stiffness has had on your life over the 
past 7 days 
11-point NRS (0=No impact at all, 10=A 
great deal of impact) 
35 Please circle the number that best describes the 
severity of your RA stiffness over the past 7 days 
11-point NRS (0=No stiffness, 10=Extreme 
stiffness) 
36 Please circle the number that best describes how 
important RA stiffness has been in your life over the 
past 7 days 
11-point NRS (0=Not important at all, 
10=Very important) 
37 Please circle the number that best describes how 
well you have coped with your RA stiffness over the 
past 7 days 
11-point NRS (0=Not well at all, 10=Very 
well) 
38 How much of the stiffness you have reported in the 
questions above is about joints that are permanently 
stuck? 
 
4-option Likert scale (None of the stiffness 
I have reported, A little of the stiffness I 
have reported, Quite a lot of the stiffness I 
have reported, All of the stiffness I have 
reported) 
39 Please circle the number that best describes the 
severity of your RA stiffness over a usual week when 
you are not in a flare? 
11-point NRS (0=No stiffness, 10=Extreme 
stiffness) 
40 How would you describe the overall level of morning 
stiffness you have had from the time you wake up? 
11-point NRS (0=No stiffness, 10=Very 
severe stiffness) 
41 How long does your morning stiffness last from 
waking until maximum improvement occurs?  
3-option Likert scale (Up to 1 hour, 1-3 
hours, More than 3 hours) 
42 Circle the number that best describes the stiffness 
(all over or in your joints) you felt due to your 
rheumatoid arthritis during the last week 
11-point NRS (0=No stiffness, 10=Very 
severe stiffness) 
43 How would you describe the overall level of morning 
stiffness you have had from the time you wake up? 
5-option Likert scale (No stiffness, Mild 
stiffness, Moderate stiffness, Severe 
stiffness, Very severe stiffness) 
44 How long does your morning stiffness last from 
waking until maximum improvement occurs? 
Minutes/Hours 
45 Were your joints stiff when you woke up today? 
(Yes/No) If yes, how long did this extra stiffness last? 
 
6-option Likert scale (Less than 30 minutes, 
30 minutes to an hour, 1-2 hours, 2-4 hours, 
More than 4 hours but less than all day, All 
day) 
 
 
